Hospital Regional Universitario de Málaga-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2022

  1. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

    The Lancet Oncology, Vol. 23, Núm. 5, pp. 659-670

2020

  1. FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: The randomised phase III VISNÚ-1 trial

    ESMO Open, Vol. 5, Núm. 6

  2. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer

    New England Journal of Medicine, Vol. 383, Núm. 23, pp. 2207-2218

2017

  1. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 227-235

2014

  1. Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 11, pp. 942-953

2011

  1. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

    Clinical and Translational Oncology, Vol. 13, Núm. 3, pp. 179-184

2008

  1. Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer

    Clinical and Translational Oncology, Vol. 10, Núm. 1, pp. 52-57

2006

  1. Polymorphisms in DNA repair genes modulate survival in cisplatin/ gemcitabine-treated non-small-cell lung cancer patients

    Annals of Oncology, Vol. 17, Núm. 4, pp. 668-675